Abatacept Launch Will Be Bolstered By Unmet Need In RA Market – Bristol
This article was originally published in The Pink Sheet Daily
Executive Summary
Bristol is focusing on rheumatoid arthritis patients who do not respond to TNF inhibitors. The initial launch material will come from Bristol's Syracuse, N.Y. facility; the company will rely on contract manufacturer Lonza to provide additional supply once a supplemental BLA is approved.